The Concept of CMR
Slides, videos and moreEvaluating CMR
Metabolic Syndrome and Type 2 Diabetes/CVD Risk
IDF
- 1Key Points (1 page)
- 2IDF Clinical Criteria for Diagnosing the Metabolic Syndrome (1 page)
- 3Etiology and Treatment of the Metabolic Syndrome and its Components According to the IDF (3 pages)
- 4IDF Clinical Tools for Diagnosing the Metabolic Syndrome and Type 2 Diabetes/CVD Risk (3 pages)
- 5References (1 page)
IDF Clinical Tools for Diagnosing the Metabolic Syndrome and Type 2 Diabetes/CVD Risk
6 of 9
One of the most important studies to tie the metabolic syndrome (as diagnosed by the IDF) to CVD mortality is the Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe (DECODE) Study. A total of 4,715 men and 5,554 women 30 to 89 years of age were drawn from nine European population-based cohorts (19). The maximum follow-up periods ranged from 7 to 16 years. Metabolic syndrome prevalence was 35.9% in men and 34.1% in women. Hazard ratios (HR) were estimated using Cox regression analysis. A total of 105 men with the metabolic syndrome died from CVD, and the unadjusted HR was 1.79 (95% CI, 1.36-2.36). A total of 47 women with the metabolic syndrome died from CVD (the unadjusted HR for women was 2.38; 95% CI, 1.55-3.65). The DECODE study also looked at the relationship between World Health Organization (WHO) clinical criteria, NCEP-ATP III guidelines, and revised NCEP-ATP III guidelines. Study findings are summarized in section Comparison of Screening Tools.
Interestingly, a cohort study of 4,350 Chinese patients with type 2 diabetes failed to find a positive association between the metabolic syndrome as defined by the IDF and CHD (myocardial infarction, ischemic heart disease, coronary revascularization, heart failure, and CHD-related death) (20). Median study follow-up was 7.1 years. Compared to subjects without the metabolic syndrome, the HR for individuals with the metabolic syndrome (as identified by the IDF) was 1.13 (95% CI, 0.86-1.48). However, the authors reached different conclusions with NCEP-ATP III clinical criteria, as discussed in section Comparison of Screening Tools.
6 of 9
